Solr Search

MI made concrete improvements to pharmaceutical research and development (R&D); leveraging funding; creating new knowledge and tools; and making Europ

rain. At the time of this report, nearly 15,000 people were diagnosed with GBM each year in the United States and Europe.

rain. At the time of this report, nearly 15,000 people were diagnosed with GBM each year in the United States and Europe.

ure disease. Both cell and gene therapies seek to modify genetic material to fight disease.

tments may be the key to unlocking the cure to debilitating genetic, oncologic, and other diseases that were once deemed incurable.

across Europe and Asia are pursuing aggressive plans to close the gap and take the high-value jobs and capital this sector creates.

selected to receive funding for research to advance understanding of the underlying biology of sarcoidosis, a poorly understood immune dysregulation con

tion with a resounding "yes" in a detailed analysis of "The Value of New Drugs" in the latest issue of The Milken Institute Review.

global powerhouse in biotechnology research — and in the ability to turn research into commercial applications, according to a new study from the Milken

gs Recap

ify Measures »